Regenxbio (RGNX) Leerink Global Healthcare Conference 2026 summary

Regulatory and clinical development updates

• Pre-BLA meeting for RGX-202 planned for mid-year, focusing on microdystrophin and functional benefit data; initial results are promising.

• Expanded access to natural history data and new analytical methods have enhanced the data package for FDA discussions.

• Approximately 50 patients will have safety exposure at the time of BLA filing, strengthening the case for accelerated approval.

• Recent leadership changes at CBER are expected to support continued use of the accelerated approval pathway.

• MPS programs (RGX-111, RGX-121) are addressing clinical hold and CRL issues, with resolution expected within months and clear biomarker strategies discussed.

Manufacturing and commercialization strategy

• Manufacturing investments have resulted in high-yield, high-purity AAV production, with consistent product profiles across clinical development.

• Rockville facility can produce 2,500 doses annually, with full control over bulk and fill-finish processes; launch inventory is being built for potential 2027 approval.

• Commercial launch readiness requires minimal additional OpEx, as manufacturing capacity and capital are already in place.

• Market opportunity for DMD has grown due to increased prevalence and dosing levels, positioning the company for significant market share.

Global and partnership opportunities

• Plans to access international markets quickly post-accelerated approval, leveraging named patient sales and potential partnerships, especially ex-U.S.

• A partner is likely for ex-U.S. commercialization due to lack of in-house sales force in Europe.

• Ophthalmology partnership with AbbVie includes a $100 million milestone for diabetic eye disease, with further cash flows supporting ongoing development.